HomeCompareSPPI vs PLD

SPPI vs PLD: Dividend Comparison 2026

SPPI yields 14.63% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.86M in total portfolio value· pulled ahead in Year 5
10 years
SPPI
SPPI
● Live price
14.63%
Share price
$1.03
Annual div
$0.15
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.2K
Annual income
$3,617.47
Full SPPI calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — SPPI vs PLD

📍 PLD pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPPIPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPPI + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPPI pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPPI
Annual income on $10K today (after 15% tax)
$1,243.90/yr
After 10yr DRIP, annual income (after tax)
$3,074.85/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,035,041.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPPI + PLD for your $10,000?

SPPI: 50%PLD: 50%
100% PLD50/50100% SPPI
Portfolio after 10yr
$2.98M
Annual income
$2,377,171.32/yr
Blended yield
79.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SPPI
Analyst Ratings
6
Buy
7
Hold
1
Sell
Consensus: Hold
Price Target
$0.75
-26.8% upside vs current
Range: $0.75 — $0.75
Altman Z
-14.1
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPPI buys
0
PLD buys
0
No recent congressional trades found for SPPI or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPPIPLD
Forward yield14.63%3.10%
Annual dividend / share$0.15$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$52.2K$5.91M
Annual income after 10y$3,617.47$4,750,725.19
Total dividends collected$24.9K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$0.75$136.00

Year-by-year: SPPI vs PLD ($10,000, DRIP)

YearSPPI PortfolioSPPI Income/yrPLD PortfolioPLD Income/yrGap
1$12,163$1,463.41$11,241$540.96+$922.00SPPI
2$14,678$1,663.56$13,019$991.13+$1.7KSPPI
3$17,582$1,876.20$15,801$1,870.97+$1.8KSPPI
4$20,913$2,100.33$20,609$3,701.21+$304.00SPPI
5← crossover$24,712$2,334.81$29,919$7,867.97$5.2KPLD
6$29,020$2,578.43$50,631$18,617.74$21.6KPLD
7$33,881$2,829.86$105,528$51,352.20$71.6KPLD
8$39,341$3,087.76$287,364$174,449.42$248.0KPLD
9$45,446$3,350.75$1,081,760$774,280.77$1.04MPLD
10$52,244$3,617.47$5,908,209$4,750,725.19$5.86MPLD

SPPI vs PLD: Complete Analysis 2026

SPPIStock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Full SPPI Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SPPI vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPPI vs SCHDSPPI vs JEPISPPI vs OSPPI vs KOSPPI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.